Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial

Area of Science:

• Urology
• Infectious Diseases
• Clinical Pharmacology

Background:

• Nongonococcal urethritis (NGU) is a common condition in men, often associated with Chlamydia trachomatis, but also potentially caused by Trichomonas vaginalis and Mycoplasma genitalium.
• Current treatment guidelines for NGU may not fully address all potential causative agents.
• Investigating alternative and combination therapies is crucial for improving treatment outcomes.

Purpose of the Study:

• To evaluate if adding tinidazole to standard treatments for NGU increases cure rates.
• To compare the efficacy of doxycycline versus azithromycin in treating NGU.
• To assess the impact of tinidazole on eradicating T. vaginalis in NGU patients.

Main Methods:

• A randomized, controlled, double-blinded phase IIB trial was conducted.
• Men diagnosed with NGU were assigned to receive either doxycycline or azithromycin, with or without tinidazole.
• Participants were monitored for up to 45 days to assess clinical cure rates and pathogen clearance.

Main Results:

• Clinical cure rates did not significantly differ between doxycycline- and azithromycin-based regimens.
• The addition of tinidazole did not improve overall cure rates but was effective in eradicating T. vaginalis.
• Doxycycline demonstrated superior clearance rates for Chlamydia trachomatis (94.8%) compared to azithromycin (77.4%).
• Azithromycin showed higher clearance rates for Mycoplasma genitalium (66.7%) than doxycycline (30.8%).

Conclusions:

• Tinidazole addition to NGU treatment regimens does not enhance overall clinical cure rates but effectively treats trichomoniasis.
• Doxycycline and azithromycin exhibit comparable clinical cure rates for NGU.
• Treatment choice between doxycycline and azithromycin should consider the likely causative pathogen, with doxycycline favored for Chlamydia and azithromycin for M. genitalium.